Elevation Oncology, Inc. (ELEV)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Joseph J. Ferra Jr. | CEO, President & Director | 897.28k | -- | 1975 |
| Dr. David Dornan Ph.D. | Chief Scientific Officer | 620.92k | -- | 1978 |
| Ms. Valerie Malyvanh Jansen M.D., Ph.D. | Chief Medical Officer | 685.94k | -- | 1978 |
| Ms. Tammy Furlong CPA, P.M.P. | CFO & Secretary | -- | -- | 1971 |
| Mr. Ryan Bloomer | Head of Tech Ops | -- | -- | -- |
| Candice Masse | Senior Director of Corporate Communications & Investor Relations | -- | -- | -- |
| Mr. Robert C. Yang | Senior VP & General Counsel | -- | -- | -- |
| Mr. Biren Shah | Senior Vice President of Business & Corporate Development | -- | -- | -- |
Elevation Oncology, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 29
Description
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Corporate Governance
Upcoming Events
November 6, 2024 at 12:30 PM UTC
Elevation Oncology, Inc. Earnings Date
Recent Events
August 6, 2024 at 12:30 PM UTC
To Discuss The Initial EO-3021 Safety and Efficacy Data Call